title: Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain.
abstract: Several papers and communications have reported possible weight reduction or less weight gain when patients start or switch to orally disintegrating olanzapine, as contrasted with standard oral olanzapine tablets. In this paper, the current literature is reviewed and hypothesized mechanisms of action are discussed. The data are still preliminary and mechanisms of action are not well understood. Randomized controlled trials are needed to further evaluate change in weight during treatment with orally disintegrating olanzapine.
authors.affiliation: Clinical Research, Eli Lilly Canada Inc., Toronto, Ontario, Canada. karagianis_jamie@lilly.com
authors.forename: Jamie
authors.initials: J
authors.lastname: Karagianis
authors.forename: Vicki Poole
authors.initials: VP
authors.lastname: Hoffmann
authors.forename: Belen
authors.initials: B
authors.lastname: Arranz
authors.forename: Tamás
authors.initials: T
authors.lastname: Treuer
authors.forename: Gerald A
authors.initials: GA
authors.lastname: Maguire
authors.forename: Lieuwe
authors.initials: L
authors.lastname: de Haan
authors.forename: Bharat
authors.initials: B
authors.lastname: Chawla
mesh_terms: D000284:Administration, Oral; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D016503:Drug Delivery Systems; D006801:Humans; D000077152:Olanzapine; D010349:Patient Compliance; D012559:Schizophrenia / Q000188:drug therapy; D012995:Solubility; D013607:Tablets; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D013607:Tablets; D001569:Benzodiazepines; D000077152:Olanzapine